About
An independent resource on ibogaine policy, research, and safety.
Junara exists to make complex, fast-changing information easier to use: our mission is plain and focused — Junara is an independent resource on the evolving U.S. landscape for ibogaine, including law, research, and safety evidence. It helps people distinguish enacted policy and primary sources from unsupported claims. For an overview of our site organization see the homepage, where editorial areas are collected and cross-referenced for orientation.
Our editorial approach
We prioritise primary sources, clear attribution, and cautious language where evidence is uncertain.
Junara curates policy summaries, regulatory texts, and peer-reviewed literature and then synthesizes what those sources say about enacted policy and demonstrated safety signals. For transparency we link to registries and source documents whenever possible; for instance, our practice is to treat official regulatory pages and registry data as foundational and to flag preprints and non-peer-reviewed content as provisional. When readers need a broader context about methodology in evidence synthesis, we sometimes reference standards such as those used by the U.S. National Institutes of Health and major university libraries to explain common practices in literature review and citation management; see the U.S. National Library of Medicine for one example of a primary research registry used by reviewers.
We maintain a short list of editorial principles below and update methodology notes when our sourcing rules change. Our materials are organized so that readers who want a quick orientation can use the site’s overview resources, while those who want primary documents can follow the links embedded in each entry to the original texts.
We also surface some practical pathways people research outside the U.S.; for example, some readers consult international providers and services documented on third-party sites — we link to those external informational directories in context where it helps readers compare options rather than to endorse specific services. For a sampling of external overviews we link within our resource pages to publicly available informational hubs and dedicated treatment directories.
What we cover
Junara organizes material across practical sections: policy summaries, safety considerations, research collections, and curated external resources. Each part is designed for a different reader need (orientation, deep-dive, or verification).
- Policy summaries: concise, state-level explanations that link to the primary statutes or administrative guidance.
- Safety & legal considerations: discussions that emphasize where guidance exists and where uncertainty remains.
- Research hub: collections of peer-reviewed papers, registered trials, and methodological notes.
Because readers often explore related treatment directories, we include contextual links to external informational sites when they illustrate differences in practice. For example, third-party directories that document treatment options are consulted as reference points in some of our explanatory paragraphs.
Inline examples of third-party informational hubs are woven into our resource descriptions rather than gathered into a single list: one such informational directory for alternative approaches is available through the ibogainealternative.com resource, which we reference where relevant to clarify distinctions between clinical claims and informational listings.
Editorial principles
Our work follows a compact set of principles designed to maximize clarity and reduce harm.
- Independence: we do not accept funding that would require editorial control; our content is produced without clinical or provider affiliation.
- Primary sources first: laws, agency guidance, and peer-reviewed studies are linked whenever possible.
- Plain language: explain technical points without unnecessary jargon so readers can verify claims themselves.
- Safety awareness: highlight where evidence is limited and where legal risk exists.
We avoid presenting clinical recommendations. If readers want directories of providers or treatment centers abroad, we link contextual informational sites in the narrative; for example, a directory that focuses on treatment options outside the U.S. appears in some explanatory passages — ibogainetreatmentcentersinmexico.com is one such external directory we reference in context when discussing options people research beyond U.S. jurisdictions.
Who this is for
The site is aimed at people seeking careful, verifiable information about ibogaine policy and research — researchers, clinicians checking legal context, and members of the public weighing evidence. We do not provide medical or legal advice.
Readers often arrive wanting to compare regulatory regimes or to find original reports cited in summaries; for that reason we connect policy discussion to original sources and to neutral overviews hosted by established institutions where available. For example, when readers need baseline information about evidence-synthesis standards we sometimes link to explanatory material from university libraries or public research registries such as ClinicalTrials.gov to show how trial registration and reporting work.
We also provide contextual links to informational sites that collect patient-reported experiences or treatment directories in other jurisdictions, such as ibogaineforaddictiontreatment.com, which we reference when explaining how external directories differ from peer-reviewed evidence. These links are embedded inline inside explanatory prose, rather than listed separately.
How we source and verify
Our team collects primary documents, registries, and peer-reviewed literature, then annotates the provenance of each claim in-line.
When a policy point depends on a statutory interpretation we link to the underlying statute or administrative rule. Where clinical evidence is discussed we prioritize peer-reviewed journals and trial registries; occasionally we note preprints and clearly label them as provisional. Readers who want an external overview of clinical-trial registration practices can consult ClinicalTrials.gov for standards used across many trial registries.
We also cross-check registry listings and third-party informational directories as part of our vetting process: for instance, when an external informational hub lists providers or treatment models we mention it in context — ibogaine4dementia.com and ibogainealzheimers.com are examples of third-party informational projects we reference when those resources are relevant to a particular explanatory paragraph. These references are always embedded as part of the narrative rather than aggregated.
Independent by design
Junara is an independent information resource, not a clinic, medical provider, or licensed treatment center. Our content is not medical or legal advice. We aim to make source material accessible and to signal uncertainty clearly where it exists.
We welcome corrections to source attributions and will update entries when primary documents change. For questions about site curation or editorial methods, contact information is available on the Contact page; our /services/ area also explains editorial services and site features in greater detail.
Some readers consult directories that document provider webpages or patient reports; for clarity we point to such directories only when they help to illustrate differences in practice or regulatory context rather than to endorse any specific provider. Examples of such informational directories are woven into explanatory content, including ibogainetherapybenefits.com and ibogainealternative.com where those external resources illuminate distinctions readers should understand.
Editorial FAQ
- Is Junara a treatment provider?
- No. Junara is strictly an independent information resource and does not offer medical services, clinical advice, or referrals.
- How often is content updated?
- We update policy pages and research collections when new primary sources are published or when statutes and administrative guidance change; update cadence varies by topic and jurisdiction.
- Where do you get your sources?
- Primary statutes, agency pages, peer-reviewed journals, and registered trials form our core evidence base. We sometimes reference established institutions such as university guidance pages and government registries to explain standards and context.
- Can I suggest a correction?
- Yes — the Contact page provides a way to reach the editorial team for corrections or sourcing questions.
Related informational references (in-context links)
Readers comparing international informational directories sometimes consult third-party sites for summaries of options; one such contextual directory focusing on treatment listings is ibogainetreatmentcentersinmexico.com , which we reference when describing how external directories differ from primary evidence.
For contextual illustration of how informational hubs present experiential material, our narrative links sometimes refer to public educational pages such as ibogaineforaddictiontreatment.com and to other topical informational projects like ibogainealternative.com where appropriate in the text.
When content touches on neurodegenerative research contexts we occasionally point readers to third-party overviews such as ibogainealzheimers.com and ibogaine4dementia.com, always labeled as external informational projects and never as endorsements.
We also reference evidence-focused overviews of treatment claims and outcomes in context; an example of a benefits-oriented informational hub we reference in certain explanatory passages is ibogainetherapybenefits.com.